One year of treatment with Viking Therapeutics’ candidate VK2809 safely and effectively reduces liver fat content, damage, and scarring in adults with nonalcoholic steatohepatitis…
The HealthWell Foundation, a charity that helps people who can’t afford to pay their medical bills, has started a new fund to support those…
Physicians from the GI Alliance, the largest physician-led network of gastroenterologists in the U.S., are now actively prescribing Rezdiffra (resmetirom) to eligible people…
Can-Fite BioPharma has been approved to enroll U.S. patients in its ongoing Phase 2b clinical trial of the oral treatment candidate namodenoson in people…
An intermittent fasting regimen reduced liver fat buildup and lowered the likelihood of liver cancer in mouse models of metabolic dysfunction-associated steatohepatitis (MASH), a severe…
Reduced activity of a protein called GPR75 appears to help prevent the buildup of fat in the liver and the subsequent development of metabolic dysfunction-associated…
The U.S. government soon will launch a first national study to assess the prevalence of metabolic dysfunction-associated steatotic liver disease, or MASLD — a liver…
FXR314, an investigational oral therapy, safely and effectively reduced liver fat content in adults with a severe form of fatty liver disease called metabolic…
The approval of Rezdiffra (resmetirom) last month in the U.S. as the first ever treatment for nonalcoholic steatohepatitis (NASH), a severe type of…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to DD01 as a potential treatment for a severe manifestation of fatty…
